Drug Trial Radar · NCT05860582
A Study of [14C]GB491 in Male Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Sep 14, 2022
Primary completion
Nov 14, 2022
Study completion Nov 14, 2022
Sponsor
- Lead sponsor
- Genor Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, single-center study to evaluate the mass-balance and pharmacokinetics of GB491 in 4-8 healthy male subjects receiving a single oral 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491. This study will help understand how the drug appears in the blood, urine, and feces after it is administered. In addition, this study will also evaluate the safety of a single dose of \[14C\]GB491 when given to healthy subjects.
Conditions
- Breast Cancer
- Nonsmall Cell Lung Cancer
Interventions
[14C]GB491Drug
A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total radioactivity in plasma PKTime frame: Up to 168 hours post dose
- Total radioactivity in urine and fecal samplesTime frame: Up to 360 hours post dose
- Metabolite G1T30 and other major matabolites (if applicable)Time frame: Up to 168 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.